Skip to main content
Fig. 2 | World Journal of Surgical Oncology

Fig. 2

From: Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective

Fig. 2

Overall survival curves of PDAC patients who did not receive postoperative chemotherapy with CDDP plus gemcitabine or S-1, GnP, or FOLFIRINOX. a Overall survivals of the UFS and NAC groups. b Comparison of the overall survivals between the UFS and NAC groups adjusted for the pathologic stage. c Overall survival of the UFS and NAC (GS) groups. d Comparison of the overall survivals between the UFS and NAC (GS) groups adjusted for the pathologic stage. PDAC, pancreatic ductal adenocarcinoma; CDDP, cisplatin; S-1, tegafur/gimeracil/oteracil, GnP, gemcitabine plus nab-paclitaxel, FOLFIRINOX, 5-fluorouracil/leucovorin plus irinotecan plus oxaliplatin; UFS, upfront surgery; NAC, neoadjuvant chemotherapy; GS, gemcitabine plus S-1

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us